AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to ...
Every time our body encounters a new disease-causing agent, a crucial defense system called adaptive immunity comes into play ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback